BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...appears to be advancing, with companies presenting first-in-human data from four candidates. The list includes HuMax-AXL-ADC...
...4 SD > 4 months 3001 Genmab A/S (CSE:GEN;Pink:GMXAY) /Seattle Genetics Inc. (NASDAQ:SGEN) Enapotamab vedotin (HuMax-AXL-ADC...
BioCentury | Feb 22, 2019
Targets & Mechanisms

Expansion into TNBC

...expression of AXL, making the cells more susceptible to Genmab A/S’ ADC against the target, HuMax-AXL-ADC...
BioCentury | Jun 28, 2018
Distillery Therapeutics

Cancer

...Phase I/II testing for NSCLC, pancreatic cancer, prostate cancer and solid tumors. Genmab A/S has HuMax-AXL-ADC...
BioCentury | Jan 25, 2018
Targets & Mechanisms

Unexpected combinations

...pathway inhibition. In the Nature Medicine study, the team showed Genmab A/S’s antibody-drug conjugate (ADC), HuMax-AXL-ADC...
...Genmab A/S (CSE:GEN; Pink:GMXAY) showed MAPK pathway inhibitors (orange pill) and Genmab’s antibody-drug conjugate (ADC) HuMax-AXL-ADC...
...orange cells) or AXL-high (yellow cells) , respectively. MAPK inhibitors increased the tumor’s susceptibility to HuMax-AXL-ADC...
BioCentury | Jan 15, 2018
Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

...generally sensitive to the drugs. In this study, researchers used Genmab's antibody-drug conjugate (ADC), called HuMax-AXL-ADC...
...combination, adding HuMax-AXL-ADC as a third treatment increased survival compared with the MAPK inhibitors or HuMax-AXL-ADC...
...patient-derived melanoma cell lines, suggesting the treatment made the remaining resistant cells susceptible to HuMax-AXL-ADC. HuMax-AXL-ADC...
BioCentury | Dec 9, 2017
Strategy

Genmab’s second act

...rights to two of the 10 clinical products in its clinical pipeline: tisotumab vedotin and HuMax-AXL-ADC...
...pivotal Phase II trial next year to treat cervical cancer. Genmab has exclusive rights to HuMax-AXL-ADC...
...TF; CD142; thromboplastin) armed with monomethyl auristatin E (MMAE). Genmab also retains full rights to HuMax-AXL-ADC...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...in at least 11 deals, with five molecules in clinical testing. The most advanced is HuMax-AXL-ADC...
BioCentury | Dec 15, 2016
Targets & Mechanisms

Keeping the Gas off AXL

...containing a conditionally active biologic (CAB) and targeting AXL Solid tumors Preclinical Genmab A/S (CSE:GEN) HuMax-AXL-ADC...
...differentiated from the antibody-based compounds in development by its decoy mechanism. Two of those - HuMax-AXL-ADC...
BioCentury | Dec 10, 2015
Top Story

Genmab describes Darzalex-fueled pipeline

...named 11 preclinical programs for which it could submit an IND by 2019. They include HuMax-AXL-ADC...
BioCentury | Sep 22, 2014
Company News

Seattle Genetics, Genmab deal

...Seattle Genetics granted Genmab rights to use antibody-drug conjugate (ADC) technology with Genmab's cancer candidate HuMax-AXL-ADC...
Items per page:
1 - 10 of 10